CleneFRA:84C0 +1.24%27 EBITDA Margin % is -46,207.69% as of Mar. 2026. GuruFocus rates FRA:84C0 with a GF Score™ of 27/100 and a GF Value™ of €0.74 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,953 Consumer Packaged Goods companies, Clene ranks worse than 99.9% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Clene's EBITDA for the
three
months ended in Mar. 2026 was €-6.01 Mil. Clene's Revenue for the
three
months ended in Mar. 2026 was €0.01 Mil. Therefore, Clene's EBITDA margin for the quarter that ended in Mar. 2026 was -46,207.69%.
Clene (FRA:84C0) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Clene EBITDA Margin % Related Terms
Clene EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Clene's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:84C0 vs BHST, GWLL, FTLF: EBITDA Margin % Comparison
For the Packaged Foods subindustry, Clene's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clene EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Clene's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Clene's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clene (FRA:84C0) has a EBITDA Margin % of -46,207.69% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clene and its competitors. According to the industry distribution chart, Clene ranks #1951 out of 1953 companies in the Consumer Packaged Goods industry, placing it in the top 99.9%.
Is Clene's EBITDA Margin % too high?
Clene's current EBITDA Margin % is -46,207.69%. Based on the distribution chart, Clene ranks #1951 out of 1953 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Clene has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clene's EBITDA Margin % compare to BHST and GWLL?
According to the Consumer Packaged Goods industry distribution chart, Clene ranks #1951 out of 1953 companies for EBITDA Margin %. This places Clene in the lower half of its industry. The industry median EBITDA Margin % is 8.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.99, based on 1,953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clene and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clene's current EBITDA Margin % is -46,207.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clene stock overvalued right now?
Based on GuruFocus' analysis, Clene (FRA:84C0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.74, compared to a current price of €4.90 — trading 562.2% above its estimated fair value. The current EBITDA Margin % is -46,207.69%. Clene's overall GF Score™ is 27/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Clene (FRA:84C0), the current EBITDA Margin % is -46,207.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clene (FRA:84C0) Overvalued in 2026?
Based on GuruFocus' analysis, Clene stock appears to be overvalued.
The current stock price of €4.90 is trading 562.2% above its estimated GF Value™ of €0.74.
GuruFocus considers Clene to be Significantly Overvalued.
Key valuation signals for FRA:84C0:
EBITDA Margin %: -46,207.69%
GF Value™: €0.74 vs. price of €4.90 (562.2% above fair value)
No single metric tells the full story. See the FRA:84C0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
27GF Score
Get the complete analysis for FRA:84C0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:84C0 has been successfully added to your 
